The immunosuppressive action by anti-PD-1 works in the effector phase of the interaction between T lymphocytes and tumor cells, and the blockade of this agent seems to be more effective towards T-cell activation than CTLA-4 blockade. This evidence concerns the gene CTLA4 and neoplasm.